Skip to main content
Caplight Logo









RedCloud Bio

RedCloud Bio

Private
ShanghaiHealthcare & Life Scienceshttp://www.redcloudbio.com/

Last Round

Series B

Extension

May 15, 2023

Total Funding Raised

$29.65M

Company Overview

RedCloud Bio is a biotechnology company that integrates structural pharmacology and computational technologies to discover and develop small molecule drugs for cancer and other severe diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Infrastructure

Keywords

small molecule therapeuticsdrug discoverynon-small cell lung cancerNSCLCstructural pharmacologycomputational drug discoveryin silico drug designtyrosine kinase inhibitorTKIai-driven drug discoverymolecular dynamicsprecision medicineoncology therapeuticsbiotechdrug resistance

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

RedCloud Bio Comparables

Compare RedCloud Bio with similar companies based on industry and business-model similarity.

RedCloud Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
J INTS BIO
87%
Eli Lilly and Company
86%
Black Diamond Therapeutics
77%

RedCloud Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionMay 15, 2023
Series BJun 17, 2021
Series ANov 30, 2019
SeedJul 1, 2018

RedCloud Bio Investors

Notable investors and investment history

RedCloud Bio investors
InvestorRounds
Kaitai CapitalSeries B
Co-Win VenturesSeries B
Sherpa Healthcare PartnersSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 1, 2025

    Monthly visitors increased 833% MoM.

  • May 15, 2023

    $14.15M raised in Series B Extension round.

RedCloud Bio Filings

Explore SEC and related filing metadata, where available.

RedCloud Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about RedCloud Bio's valuation, stock price, and market status.

Is RedCloud Bio a public or private company?

RedCloud Bio is a private company.

What is the current stock price of RedCloud Bio?

RedCloud Bio is a private company with no public stock price. No recent secondary market data is available.

How much is RedCloud Bio worth (valuation)?

Valuation information for RedCloud Bio is not publicly available.

Can I buy RedCloud Bio stock?

RedCloud Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was RedCloud Bio's last funding round?

RedCloud Bio's most recent funding round was Series B Extension on May 15, 2023.

Who are the main investors in RedCloud Bio?

Key investors in RedCloud Bio include Co-Win Ventures.

Will RedCloud Bio IPO soon?

No public IPO plans have been announced for RedCloud Bio.

How can I track RedCloud Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor RedCloud Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersShanghai
Employee Range1
Year Founded2022
Last FundingMay 15, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?